Kamau Therapeutics
Ryan S. is a finance and operations professional with a robust background in investment and board governance across various high-tech and biomedical companies. Currently a member of the founding team at Kamau Therapeutics since May 2023, Ryan previously served as a board member at Forterra, where leadership included a successful Series A funding round. Other roles involve board observer contributions at ArsenalBio, Opentrons Labworks Inc., Synthego Corporation, Umoja Biopharma, and AutoStore™, as well as investor positions at Symbotic and Neuron23. Ryan's educational background includes a Bachelor of Arts in Economics and Accounting from UCLA, alongside an incomplete Bachelor of Science in Aerospace Engineering from UC Santa Barbara and a high school diploma from Bellevue High School.
This person is not in any teams
This person is not in any offices
Kamau Therapeutics
Kamau Therapeutics is a clinical-stage, next-generation gene correction company harnessing high efficiency targeted gene integration to develop a new class of therapies with the aim to cure a wide range of serious and life-threatening diseases. Our novel gene correction approach, called homology-directed repair (HDR), overcomes prior limitations in specificity, efficiency, and durability of gene editing to offer broad potential for transforming human health outcomes through the delivery of one-time curative cell therapies. Our platform aims treat or cure a range of serious genetic diseases with unmet medical needs.